VC Playbook

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

In Vivo looks at the top partnerships and investments in AI-driven companies in 2024. Collaborations and investments spanned multiple therapeutic areas, with a particular focus on small molecule discovery, protein degradation and neurological diseases.

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

Success in life sciences venture funding requires drive and speed, says In Vivo Rising Leader, Clare Terlouw. But there is more to it than that.  

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

VC Playbook: Hubert Birner, managing partner for Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment approach and global fund operations. At the November 2023 BIO-Europe conference, he sat down with In Vivo to discuss the VC’s strategy and expectations for the European life science sector in 2024.  

VC Playbook: Bradley Hardiman, senior director of business development at Astellas Venture Management, discusses setting a CVC strategy when the biopharma market is in a “state of flux.”  

Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.  

Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.  

Created by Steve Lehmann, director of venture operations at Portal Innovations, Stargaze is an artificial intelligence platform that maps the structure of biotechnology innovation and uses that knowledge to identify fruitful startups.